Phase 1 clinical trial of eneboparatide, a novel PTH receptor 1 agonist
Mark Sumeray, Michael D. Culler, Michel Ovize, Soraya Allas et al.
Citations
1 citations
Journal
Endocrine Connections
Topics
Thyroid and Parathyroid Surgery
Field-Weighted Citation Impact (FWCI)
2.01
article
Phase 1 clinical trial of eneboparatide, a novel PTH receptor 1 agonist
Mark Sumeray, Michael D. Culler, Michel Ovize, Soraya Allas, Taha OuldRouis, Michael Mannstadt, Jeroen van de Wetering de Rooij, Stéphane Milano
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
Endocrine ConnectionsVol. 14(6)
Institutions
Boston University (US), Harvard University (US), MGH Institute of Health Professions (US), Massachusetts General Hospital (US), Erytech Pharma (France) (FR), PRA Health Sciences (US)
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
Phase 1 clinical trial of eneboparatide, a novel PTH receptor 1 agonist — Mark Sumeray, Michael D. Culler, et al. · Endocrine Connections (2025) | TGRS Research Map | TGRS